uniQure (NASDAQ:QURE) Director Jeremy Springhorn Sells 1,993 Shares

uniQure N.V. (NASDAQ:QURE) Director Jeremy Springhorn sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the transaction, the director owned 43,251 shares of the company’s stock, valued at approximately $1,170,372.06. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

uniQure Stock Performance

Shares of NASDAQ:QURE traded up $0.75 during trading on Friday, hitting $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a 50-day simple moving average of $22.31 and a two-hundred day simple moving average of $21.76.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. On average, equities research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Trading of uniQure

Institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp grew its holdings in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. CIBC Private Wealth Group LLC acquired a new stake in uniQure in the third quarter valued at approximately $50,000. Torren Management LLC acquired a new stake in uniQure in the fourth quarter valued at approximately $28,000. FNY Investment Advisers LLC grew its holdings in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares during the period. Finally, IFP Advisors Inc acquired a new stake in uniQure in the fourth quarter valued at approximately $48,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. HC Wainwright reduced their price target on uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Finally, Wolfe Research assumed coverage on uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.